Tolcapone and Hepatotoxic Effects
C. Warren Olanow, MD, FRCPC;
and the Tasmar Advisory Panel
Arch Neurol. 2000;57:263-267.
Four patients with Parkinson disease have recently been described in whom severe hepatic dysfunction developed in association with tolcapone therapy. These reports led to the introduction of a "black box" warning and more intensive monitoring requirements in the United States. A review of these cases and all clinical trials indicates that liver dysfunction did not develop in any patient who had received monitoring of liver function according to the original prescribing information. Virtually all instances of liver enzyme abnormality and clinical liver dysfunction occurred within 6 months of initiating treatment. To assess the current role of tolcapone therapy in Parkinson disease, a panel of neurologists and hepatologists was convened. Consensus was reached with respect to the following: (1) Tolcapone is an effective agent in the treatment of patients with fluctuating Parkinson disease. (2) The risk of developing irreversible liver injury is negligible with appropriate monitoring. (3) It may be possible to reduce the frequency of monitoring after 6 months of treatment. (4) The requirement that tolcapone be withdrawn if liver enzymes are elevated above the upper limit of normal on a single occasion is unnecessarily restrictive. It was concluded that tolcapone, when used as an adjunct to levodopa, is an effective anti-parkinsonian agent and that less frequent monitoring after 6 months, with an action limit of 2 to 3 times the upper limit of normal, is sufficient to ensure safety in patients who are deriving benefit from the drug.
From the Department of Neurology, Mount Sinai School of Medicine, New York, NY. The editorial content of this article expresses the views of the individual contributors and does not necessarily reflect the views or recommendations of Roche Laboratories Inc. All of the advisors have served as paid consultants for Roche Laboratories Inc.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(2):284-285.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
Lees et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:944-948.
ABSTRACT
| FULL TEXT
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Pahwa et al.
Neurology 2006;66:983-995.
ABSTRACT
| FULL TEXT
ASSESSMENT OF CATECHOL INDUCTION AND GLUCURONIDATION IN RAT LIVER MICROSOMES
Elovaara et al.
Drug Metab. Dispos. 2004;32:1426-1433.
ABSTRACT
| FULL TEXT
Drug-Induced Hepatotoxicity
Lee
NEJM 2003;349:474-485.
FULL TEXT
Parkinson's disease and anaesthesia
Nicholson et al.
Br J Anaesth 2002;89:904-916.
ABSTRACT
| FULL TEXT
An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
Olanow et al.
Neurology 2001;56:S1-S88.
FULL TEXT
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Pahwa et al.
Neurology 2006;66:983-995.
ABSTRACT
| FULL TEXT
|
